Vardenafil: Difference between revisions

Jump to navigation Jump to search
m (Protected "Vardenafil": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 25: Line 25:
{{CMG}}
{{CMG}}


{{Editor Join}}
 


==[[Vardenafil (patient information)|For patient information, click here]]==
==[[Vardenafil (patient information)|For patient information, click here]]==
Line 72: Line 72:
{{Urologicals}}
{{Urologicals}}
{{Phosphodiesterase inhibitors}}
{{Phosphodiesterase inhibitors}}
{{SIB}}
 


[[Category:PDE5 inhibitors]]
[[Category:PDE5 inhibitors]]

Revision as of 17:18, 20 August 2012

Vardenafil
Clinical data
Pregnancy
category
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
Pharmacokinetic data
Bioavailability15%
Protein binding95%
MetabolismHepatic (CYP3A4)
Elimination half-life4–5 hours
ExcretionBiliary
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H32N6O4S
Molar mass488.604 g/mol

WikiDoc Resources for Vardenafil

Articles

Most recent articles on Vardenafil

Most cited articles on Vardenafil

Review articles on Vardenafil

Articles on Vardenafil in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Vardenafil

Images of Vardenafil

Photos of Vardenafil

Podcasts & MP3s on Vardenafil

Videos on Vardenafil

Evidence Based Medicine

Cochrane Collaboration on Vardenafil

Bandolier on Vardenafil

TRIP on Vardenafil

Clinical Trials

Ongoing Trials on Vardenafil at Clinical Trials.gov

Trial results on Vardenafil

Clinical Trials on Vardenafil at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Vardenafil

NICE Guidance on Vardenafil

NHS PRODIGY Guidance

FDA on Vardenafil

CDC on Vardenafil

Books

Books on Vardenafil

News

Vardenafil in the news

Be alerted to news on Vardenafil

News trends on Vardenafil

Commentary

Blogs on Vardenafil

Definitions

Definitions of Vardenafil

Patient Resources / Community

Patient resources on Vardenafil

Discussion groups on Vardenafil

Patient Handouts on Vardenafil

Directions to Hospitals Treating Vardenafil

Risk calculators and risk factors for Vardenafil

Healthcare Provider Resources

Symptoms of Vardenafil

Causes & Risk Factors for Vardenafil

Diagnostic studies for Vardenafil

Treatment of Vardenafil

Continuing Medical Education (CME)

CME Programs on Vardenafil

International

Vardenafil en Espanol

Vardenafil en Francais

Business

Vardenafil in the Marketplace

Patents on Vardenafil

Experimental / Informatics

List of terms related to Vardenafil

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


For patient information, click here

Overview

Vardenafil (INN) is a PDE5 inhibitor used in the treatment of erectile dysfunction. It can assist men with this disorder in achieving and maintaining an erection during sexual activity. It is commonly marketed under the trade name Levitra (Bayer AG).

History

Vardenafil was co-marketed by Bayer Pharmaceuticals and GSK under the trade name Levitra. As of 2005, the co-promotion rights of GSK on Levitra have been "transferred back" to Bayer in many markets outside of the United States. In Italy, Bayer markets the product as Levitra and GSK markets the product as Vivanza. Due to European Union trade rules, parallel imports may result in the Vivanza branded packs being seen alongside Levitra packs in pharmacies in other EU member states.

Clinical use

Indications and contraindications are as for other PDE5 inhibitors. As a PDE5 inhibitor, vardenafil is closely related in both function and marketing to sildenafil (Viagra) and tadalafil (Cialis). Structurally, the vardenafil molecule differs from sildenafil by only a methyl group and the position of one nitrogen atom in its structure. It has a relatively short effective time, comparable to sildenafil.

Adverse drug reactions

More common adverse drug reactions (ADRs) are as per other PDE5 inhibitors and are listed on that page.

Common vardenafil-specific ADRs include: nausea. Infrequent ADRs include: abdominal pain, back pain, photosensitivity, abnormal vision, eye pain, facial oedema, hypertension, palpitation, tachycardia, arthralgia, myalgia, rash, itch, priapism. (Rossi, 2004)

The use of products containing vardenafil has also been associated with serious side-effects which include serious cardiac events such as heart attacks. In rare cases, the use of vardenafil may result in penile tissue damage and permanent loss of potency. Health Canada (2006)

On October 18, 2007, the FDA announced that a warning about possible sudden hearing loss would be added to the drug labels of vardenafil and other PDE5 inhibitors.[1]

Drug interactions

Products containing vardenafil should not be used by individuals who are taking any nitrate medication because combining these products could result in the development of potentially life-threatening low blood pressure.

Dose forms

It is available in 2.5 mg, 5 mg, 10 mg, and 20 mg doses in round orange tablets. The normal starting dose is 10 mg (roughly equivalent to 50 mg of sildenafil). Vardenafil should be taken 25–60 minutes prior to sexual activity, with a maximum dose frequency of once per day. In some territories, such as the UK, only certain doses may be available, i.e. 5 mg, 10 mg, and 20 mg.

See also

Notes

  1. "FDA Announces Revisions to Labels for Cialis, Levitra and Viagra". Food and Drug Administration.

External links

Template:Phosphodiesterase inhibitors

bg:Варденафил da:Vardenafil de:Vardenafil hu:Vardenafil fi:Vardenafiili uk:Варденафіл


Template:WikiDoc Sources